- Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial — Recruiting • Non-phase study • Oncology • NCT06915909.
- What is being tested: Feasibility of using artificial intelligence to review operative outcomes, specifically pain levels, when comparing two commonly used robotic surgical devices for prostate cancer removal.
- Patient eligibility overview: The trial involves patients undergoing robotic-assisted laparoscopic prostatectomy (RALP) for prostate cancer treatment, comparing outcomes between the two surgical platforms used in standard clinical practice.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the removal of prostate cancers. The data collected will inform methodologies for future, larger, multi-center trials investigating pain in patients undergoing prostate cancer surgery. A robotic prostatectomy is a commonly performed surgery used to treat prostate cancer by removing the prostate gland. In order to perform the procedure, the surgeon must 'inflate' (technical term pneumoperitoneum) the patients…
- : * Patient indicated for non-emergent robotic Prostatectomy surgery * Patients (or appropriate legal representatives) able to provide written informed consent to participate in the study * Males, aged 18 to 75 years * Have no significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and/or behavioural recommendations and office visits * Are American Society of Anaesthesiologists (ASA) Class I, II, or III);
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.